Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis.

Pituitary
Mattia BarbotCarla Scaroni

Abstract

Pasireotide (PAS) is an effective treatment for Cushing's disease (CD) but its use is burdened by an associated high incidence of diabetes mellitus (DM). The aim of this study was to examine the effect of a single subcutaneous injection of PAS on glucose metabolism in CD, and to identify predictors of DM onset. Fifteen patients with CD (13 females, 2 males; median age 43 years [IQR 34-50]) were submitted to an acute PAS test (600 µg s.c.), measuring glucose, insulin, C-peptide, GIP, glucagon, GLP-1, ACTH, and cortisol at the baseline and every 30 min for 2 h. Then they were treated twice daily with PAS 600 µg, and followed up with clinical and hormone assessments for a median of 6 months [2-13]. PAS prompted a significant decrease in all hormonal parameters considered except for glycemia, which increased (as expected), reaching the highest value at 120' (p < 0.0001). Overall, 9/15 patients developed DM within 2 months of starting PAS therapy. There were no differences in age, weight, visceral adiposity, HOMA index, fasting glucose or severity of CD between patients who developed DM and those who did not. Baseline fasting glucagon levels were higher in the DM patients (17.95 [12.45-20.54] vs. 10.53 [8.11-12.33] pmol/L, p = 0.025...Continue Reading

References

Jul 8, 1995·Lancet·M H DuncanJ Alaghband-Zadeh
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·M B Toft-NielsenJ J Holst
Jul 1, 2010·Diabetes Care·Xuanping ZhangAnn L Albright
Nov 26, 2010·Vitamins and Hormones·Bo AhrénCarolyn F Deacon
Mar 9, 2012·The New England Journal of Medicine·Annamaria ColaoUNKNOWN Pasireotide B2305 Study Group
Jan 4, 2013·Diabetes Care·UNKNOWN American Diabetes Association
May 21, 2013·Cell Metabolism·Jonathan E Campbell, Daniel J Drucker
Jun 5, 2013·The Journal of Clinical Endocrinology and Metabolism·Robert R HenrySunder Mudaliar
Jan 28, 2014·Diabetes Research and Clinical Practice·Astrid BreitschaftGeorg Golor
Apr 9, 2015·Nature Reviews. Endocrinology·Jonathan E Campbell, Daniel J Drucker
Jul 30, 2015·The Journal of Clinical Endocrinology and Metabolism·Lynnette K NiemanUNKNOWN Endocrine Society
Apr 30, 2016·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·L TrementinoG Arnaldi
Jan 9, 2018·Mayo Clinic Proceedings·Sofie HædersdalTina Vilsbøll
Jun 20, 2018·Frontiers in Endocrinology·Mattia BarbotCarla Scaroni
Jul 24, 2018·The Lancet. Diabetes & Endocrinology·Richard A FeeldersAndre Lacroix
Jun 6, 2019·Frontiers in Endocrinology·Mattia BarbotCarla Scaroni
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

The Journal of the American Academy of Psychiatry and the Law
Linda J Gottlieb
Nederlands tijdschrift voor geneeskunde
A M W HEKKING
Pharmaceutisch weekblad
J A W BERGHAUSER PONT
Journal de médecine de Bordeaux et du Sud-Ouest
VERIN
© 2022 Meta ULC. All rights reserved